Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $28.78M by Medicaid between Jan 2018 and Dec 2024, across 417 billing codes. Its largest line is 99283, emergency room visit (moderate) — 43% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
ANAHEIM, CA 92806
ANAHEIM, CA 92806
33aNPI1144375056assigned 01/24/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.78M
24GClaims1,897,344
24DCodes billed417
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#93 of 410
Median peer was paid$6.90M
This provider vs. median4.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 178,447 | $252K | |
| 2019 | 230,938 | $830K | |
| 2020 | 241,975 | $1.45M | |
| 2021 | 282,761 | $1.47M | |
| 2022 | 296,665 | $2.06M | |
| 2023 | 286,477 | $2.27M | |
| 2024incomplete | 380,081 | $20.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 43% | 81,217 | 74,282 | $12.49M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.2% | 8,648 | 8,173 | $2.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 9,317 | 8,934 | $1.31M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 3.7% | 1,339 | 1,284 | $1.07M |
| G0378 | Hospital observation service, per hour | 3.6% | 9,073 | 4,338 | $1.03M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 3.5% | 1,320 | 1,316 | $1.02M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 11,514 | 11,274 | $885K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 9,515 | 9,091 | $415K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 17,444 | 16,014 | $339K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.1% | 2,334 | 2,302 | $325K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 523 | 519 | $315K |
| 0450 | Emergency room services | 1.0% | 23,731 | 20,626 | $295K |
405 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.0% | 16,909 | $291K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,310 | $271K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,901 | $215K |
| 86900 | <1% | 9,127 | $180K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,461 | $179K |
| 93017 | <1% | 591 | $174K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,203 | $166K |
| 86885 | <1% | 5,382 | $159K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,018 | $144K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,219 | $130K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,533 | $121K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,746 | $120K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 85,541 | $117K |
| 80051 | <1% | 86,711 | $113K | |
| 72141 | <1% | 1,563 | $112K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,707 | $111K |
| 82565 | <1% | 102,322 | $104K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,395 | $93K |
| 71250 | <1% | 1,277 | $91K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,106 | $89K |
| 78451 | <1% | 71 | $84K | |
| 94060 | <1% | 712 | $77K | |
| 73221 | <1% | 689 | $75K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,685 | $72K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 14,804 | $71K |
| 83880 | <1% | 8,483 | $66K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,017 | $64K |
| 93971 | <1% | 1,585 | $63K | |
| 70486 | <1% | 1,271 | $60K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22,389 | $59K |
| 84460 | <1% | 57,960 | $58K | |
| 87505 | <1% | 1,815 | $56K | |
| 86923 | <1% | 435 | $56K | |
| 70496 | <1% | 258 | $54K | |
| 86901 | <1% | 9,131 | $53K | |
| 84702 | <1% | 16,021 | $52K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 453 | $52K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 710 | $48K |
| 84520 | <1% | 74,099 | $48K | |
| 70498 | <1% | 233 | $46K | |
| 70491 | <1% | 332 | $46K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 31,884 | $45K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,088 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,054 | $45K |
| 82247 | <1% | 43,747 | $44K | |
| 74183 | <1% | 165 | $43K | |
| 82947 | <1% | 68,709 | $42K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 22,677 | $41K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,909 | $40K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,174 | $39K |
| 83970 | <1% | 2,748 | $38K | |
| 73562 | <1% | 2,441 | $38K | |
| 80061 | Lipid panel | <1% | 18,016 | $38K |
| 73630 | <1% | 2,847 | $37K | |
| 94726 | <1% | 376 | $37K | |
| 84075 | <1% | 39,178 | $37K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,626 | $37K |
| 85027 | <1% | 46,535 | $37K | |
| 90686 | <1% | 6,350 | $36K | |
| 81003 | <1% | 69,848 | $36K | |
| 74178 | <1% | 85 | $35K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 580 | $35K |
| 72100 | <1% | 1,557 | $33K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,399 | $33K |
| 73610 | <1% | 2,491 | $33K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,338 | $32K |
| 84450 | <1% | 31,100 | $31K | |
| 73030 | <1% | 2,230 | $31K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 420 | $31K |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 339 | $30K |
| 74018 | <1% | 2,335 | $30K | |
| 94729 | <1% | 371 | $30K | |
| 83690 | <1% | 24,028 | $29K | |
| 99199 | Unlisted special service, procedure or report | <1% | 597 | $29K |
| 76801 | <1% | 1,207 | $29K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,507 | $28K |
| 86141 | <1% | 7,426 | $28K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,447 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,120 | $27K |
| 82310 | <1% | 23,368 | $26K | |
| 72197 | <1% | 64 | $26K | |
| 85610 | <1% | 25,381 | $26K | |
| 88184 | <1% | 85 | $25K | |
| 72146 | <1% | 174 | $25K | |
| 78306 | <1% | 80 | $25K | |
| 0637 | <1% | 87,819 | $24K | |
| 86780 | <1% | 7,266 | $23K | |
| 84484 | <1% | 16,721 | $23K | |
| 83735 | <1% | 17,742 | $23K | |
| 82728 | <1% | 7,385 | $22K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,971 | $21K |
| 93970 | <1% | 225 | $21K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,394 | $20K |
| 81513 | <1% | 452 | $20K | |
| 86803 | <1% | 4,698 | $19K | |
| 80076 | <1% | 3,475 | $19K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,019 | $19K |
| 86480 | <1% | 880 | $18K | |
| 73502 | <1% | 873 | $17K | |
| 82570 | <1% | 9,696 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,224 | $16K |
| 73110 | <1% | 1,401 | $16K | |
| 72131 | <1% | 111 | $16K | |
| 87088 | <1% | 12,945 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,453 | $15K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,910 | $15K |
| 82607 | <1% | 4,533 | $14K | |
| 83520 | <1% | 1,949 | $14K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,662 | $14K |
| 73130 | <1% | 1,316 | $14K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 634 | $14K |
| 87340 | <1% | 6,217 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,917 | $13K |
| 82077 | <1% | 3,984 | $12K | |
| 87040 | <1% | 7,901 | $12K | |
| 76870 | <1% | 535 | $12K | |
| 83550 | <1% | 6,873 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 207 | $12K |
| 76380 | <1% | 156 | $12K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,582 | $11K |
| 84156 | <1% | 9,163 | $10K | |
| 73080 | <1% | 725 | $10K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,681 | $10K |
| 87497 | <1% | 302 | $10K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,295 | $10K |
| 84100 | <1% | 10,000 | $10K | |
| 72156 | <1% | 24 | $9K | |
| 80306 | <1% | 2,292 | $9K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 762 | $9K |
| 87481 | <1% | 493 | $9K | |
| 83021 | <1% | 2,869 | $9K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 453 | $9K |
| 73718 | <1% | 43 | $9K | |
| 73140 | <1% | 977 | $9K | |
| 83540 | <1% | 7,041 | $9K | |
| 86762 | <1% | 3,188 | $8K | |
| P9021 | Red blood cells, each unit | <1% | 220 | $8K |
| 80179 | <1% | 2,618 | $8K | |
| 82746 | <1% | 2,316 | $8K | |
| 82040 | <1% | 7,749 | $8K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 788 | $8K |
| 82248 | <1% | 9,366 | $8K | |
| 85730 | <1% | 5,712 | $8K | |
| 86787 | <1% | 3,296 | $7K | |
| 82043 | <1% | 4,057 | $7K | |
| 82105 | <1% | 1,293 | $7K | |
| 70544 | <1% | 25 | $7K | |
| 84439 | <1% | 3,593 | $7K | |
| 87449 | <1% | 2,304 | $7K | |
| 72040 | <1% | 498 | $7K | |
| 73590 | <1% | 344 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,783 | $7K |
| 83605 | <1% | 4,446 | $7K | |
| 83615 | <1% | 4,259 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 167 | $6K |
| 86765 | <1% | 1,717 | $6K | |
| 71101 | <1% | 268 | $6K | |
| 73564 | <1% | 487 | $6K | |
| 86665 | <1% | 1,304 | $6K | |
| 82950 | <1% | 5,835 | $6K | |
| 76770 | <1% | 389 | $6K | |
| 86038 | <1% | 1,762 | $6K | |
| 84403 | <1% | 1,109 | $6K | |
| 97161 | <1% | 725 | $5K | |
| 84132 | <1% | 4,883 | $5K | |
| 82951 | <1% | 1,598 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,116 | $5K |
| 84153 | <1% | 1,347 | $5K | |
| 86225 | <1% | 1,533 | $5K | |
| 86880 | <1% | 102 | $5K | |
| 84165 | <1% | 878 | $5K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 2,371 | $5K |
| 87324 | <1% | 1,609 | $5K | |
| 90656 | <1% | 731 | $5K | |
| 86704 | <1% | 1,240 | $5K | |
| 82784 | <1% | 755 | $5K | |
| 84550 | <1% | 4,603 | $5K | |
| 85379 | <1% | 2,366 | $4K | |
| 85652 | <1% | 7,904 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,813 | $4K |
| 86317 | <1% | 936 | $4K | |
| J3490 | Unclassified drugs | <1% | 8,137 | $4K |
| 80197 | <1% | 480 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,320 | $4K |
| 81015 | <1% | 2,589 | $4K | |
| 99499 | <1% | 66 | $4K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 458 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,513 | $4K |
| 86364 | <1% | 339 | $4K | |
| 74170 | <1% | 14 | $4K | |
| 82550 | <1% | 2,431 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 312 | $4K |
| 0710 | <1% | 6,100 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,628 | $3K |
| J1815 | Injection, insulin, per 5 units | <1% | 3,067 | $3K |
| 76536 | <1% | 318 | $3K | |
| 82962 | <1% | 2,689 | $3K | |
| 86334 | <1% | 151 | $3K | |
| 84295 | <1% | 3,288 | $3K | |
| 82378 | <1% | 325 | $3K | |
| 62323 | <1% | 242 | $3K | |
| 88342 | <1% | 761 | $3K | |
| 84146 | <1% | 979 | $3K | |
| 77080 | <1% | 204 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,401 | $3K |
| 86664 | <1% | 655 | $3K | |
| 87210 | <1% | 6,453 | $3K | |
| 89051 | <1% | 880 | $3K | |
| 88307 | <1% | 421 | $2K | |
| 0250 | <1% | 11,393 | $2K | |
| 88341 | <1% | 233 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 4,741 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,375 | $2K |
| 86160 | <1% | 545 | $2K | |
| 87205 | <1% | 2,477 | $2K | |
| 87081 | <1% | 2,049 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 225 | $2K |
| 83993 | <1% | 113 | $2K | |
| 87517 | <1% | 58 | $2K | |
| 73660 | <1% | 173 | $2K | |
| 87186 | <1% | 1,142 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,256 | $2K |
| 82670 | <1% | 569 | $2K | |
| 83001 | <1% | 898 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 273 | $2K |
| Z7502 | <1% | 258 | $2K | |
| 86308 | <1% | 1,411 | $2K | |
| 82952 | <1% | 1,560 | $2K | |
| 73560 | <1% | 203 | $2K | |
| 83721 | <1% | 999 | $2K | |
| 90662 | <1% | 240 | $1K | |
| 90688 | <1% | 248 | $1K | |
| 86431 | <1% | 765 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,300 | $1K |
| 76642 | <1% | 278 | $1K | |
| 82977 | <1% | 255 | $1K | |
| 73552 | <1% | 29 | $1K | |
| V2632 | Posterior chamber intraocular lens | <1% | 116 | $1K |
| 85014 | <1% | 3,052 | $1K | |
| 97116 | <1% | 294 | $1K | |
| 82150 | <1% | 556 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 210 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 582 | $1K |
| 72070 | <1% | 96 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,628 | $1K |
| 96367 | <1% | 137 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 426 | $1K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 716 | $1K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 51 | $1K |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 86 | $988.36 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,154 | $987.45 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 60 | $987.18 |
| 84134 | <1% | 157 | $982.02 | |
| 73090 | <1% | 300 | $975.88 | |
| 82805 | <1% | 161 | $974.59 | |
| 85018 | <1% | 1,474 | $949.36 | |
| 84155 | <1% | 1,056 | $944.50 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,058 | $932.99 |
| 85046 | <1% | 874 | $902.63 | |
| 73100 | <1% | 211 | $861.52 | |
| 72050 | <1% | 97 | $854.67 | |
| 83718 | <1% | 850 | $807.20 | |
| 87522 | Neg quan hep c or qual rna | <1% | 17 | $762.00 |
| 87070 | <1% | 791 | $749.53 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 575 | $739.52 |
| 90715 | <1% | 71 | $729.29 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,140 | $727.84 |
| 82140 | <1% | 85 | $714.45 | |
| 83655 | <1% | 2,693 | $664.62 | |
| 88304 | <1% | 1,320 | $655.95 | |
| 72158 | <1% | 12 | $632.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,064 | $615.71 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 215 | $594.69 |
| 82627 | <1% | 94 | $564.00 | |
| 77066 | Tomosynthesis, mammo | <1% | 73 | $563.32 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 953 | $553.65 |
| 76881 | <1% | 94 | $538.93 | |
| 86708 | <1% | 92 | $521.26 | |
| 86335 | <1% | 15 | $521.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 27 | $497.71 |
| 83935 | <1% | 104 | $486.70 | |
| 92610 | <1% | 12 | $484.41 | |
| 82465 | <1% | 875 | $479.63 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 382 | $478.35 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 786 | $472.10 |
| 84145 | <1% | 103 | $468.76 | |
| 0258 | <1% | 1,832 | $462.83 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 24 | $462.20 |
| 83930 | <1% | 107 | $457.72 | |
| 73522 | <1% | 35 | $437.87 | |
| 72081 | <1% | 118 | $432.00 | |
| 82390 | <1% | 40 | $425.00 | |
| 73120 | <1% | 29 | $415.94 | |
| 74022 | <1% | 75 | $414.04 | |
| 84478 | <1% | 96 | $405.00 | |
| 82232 | <1% | 27 | $394.86 | |
| C1769 | Guide wire | <1% | 313 | $391.20 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 895 | $353.69 |
| 86003 | <1% | 397 | $353.65 | |
| 87631 | <1% | 96 | $330.21 | |
| 87536 | <1% | 183 | $327.72 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 286 | $325.36 |
| 86304 | <1% | 16 | $319.00 | |
| 83002 | <1% | 281 | $310.00 | |
| 82330 | <1% | 27 | $304.32 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 589 | $295.53 |
| 80324 | <1% | 704 | $294.05 | |
| 86677 | <1% | 653 | $293.32 | |
| 85246 | <1% | 14 | $289.00 | |
| 97165 | <1% | 14 | $284.82 | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 161 | $278.10 |
| 90749 | <1% | 256 | $271.89 | |
| 86769 | <1% | 175 | $252.24 | |
| 86235 | <1% | 12 | $240.00 | |
| 82705 | <1% | 52 | $231.00 | |
| 82272 | <1% | 192 | $220.56 | |
| 73070 | <1% | 56 | $219.88 | |
| 12001 | <1% | 82 | $216.38 | |
| 85240 | <1% | 13 | $199.00 | |
| 84480 | <1% | 243 | $186.66 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 619 | $179.34 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 613 | $171.00 |
| 82533 | <1% | 12 | $169.00 | |
| 83010 | <1% | 28 | $156.49 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 971 | $146.96 |
| 86140 | <1% | 1,062 | $141.42 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 160 | $134.47 |
| 73000 | <1% | 39 | $117.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 95 | $114.51 |
| 86709 | <1% | 13 | $112.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 159 | $106.90 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 90 | $104.82 |
| 80320 | <1% | 372 | $99.20 | |
| 77072 | <1% | 13 | $97.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 95 | $92.28 |
| 80329 | <1% | 328 | $86.75 | |
| 80359 | <1% | 654 | $81.32 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 12 | $79.36 |
| 87184 | <1% | 13 | $67.46 | |
| 87807 | <1% | 93 | $64.71 | |
| 10060 | <1% | 15 | $60.00 | |
| 86256 | <1% | 31 | $58.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 33 | $55.88 |
| 85045 | <1% | 14 | $54.00 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 23 | $53.96 |
| 80164 | <1% | 41 | $53.35 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 81 | $52.41 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 92 | $43.80 |
| 12011 | <1% | 41 | $36.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 12 | $35.33 |
| 87045 | <1% | 47 | $33.28 | |
| J2280 | Injection, moxifloxacin, 100 mg | <1% | 138 | $31.17 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 17 | $31.13 |
| 88108 | <1% | 16 | $30.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 56 | $29.19 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 223 | $27.59 |
| 47562 | <1% | 14 | $24.95 | |
| 85384 | <1% | 34 | $24.26 | |
| 84270 | <1% | 14 | $23.00 | |
| 87046 | <1% | 13 | $15.66 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 16 | $10.05 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 63 | $6.27 |
| 29125 | <1% | 12 | $5.00 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 32 | $3.26 |
| 3074F | 0% | 372 | $0.00 | |
| 0370 | 0% | 6,272 | $0.00 | |
| 73650 | 0% | 14 | $0.00 | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 0% | 12 | $0.00 |
| 88185 | 0% | 58 | $0.00 | |
| 3044F | 0% | 4,159 | $0.00 | |
| 0636 | 0% | 1,156 | $0.00 | |
| 0350 | 0% | 76 | $0.00 | |
| 0307 | 0% | 620 | $0.00 | |
| 86376 | 0% | 13 | $0.00 | |
| 0306 | 0% | 887 | $0.00 | |
| 0305 | 0% | 1,989 | $0.00 | |
| 0301 | 0% | 8,683 | $0.00 | |
| 0610 | 0% | 24 | $0.00 | |
| 0352 | 0% | 43 | $0.00 | |
| 0612 | Calcium glucon (wg critical) | 0% | 35 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 19 | $0.00 |
| 3052F | 0% | 38 | $0.00 | |
| 0611 | 0% | 18 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 25 | $0.00 |
| 0300 | 0% | 680 | $0.00 | |
| 0272 | 0% | 1,568 | $0.00 | |
| 86359 | 0% | 159 | $0.00 | |
| 3046F | 0% | 119 | $0.00 | |
| 86360 | 0% | 159 | $0.00 | |
| 0320 | 0% | 1,320 | $0.00 | |
| 3078F | 0% | 364 | $0.00 | |
| 0402 | 0% | 406 | $0.00 | |
| 3051F | 0% | 119 | $0.00 | |
| 0302 | 0% | 638 | $0.00 | |
| 0351 | 0% | 106 | $0.00 | |
| 0403 | 0% | 70 | $0.00 | |
| 0360 | 0% | 119 | $0.00 | |
| 0921 | 0% | 14 | $0.00 | |
| 87149 | 0% | 12 | $0.00 | |
| 82274 | 0% | 13 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 19 | $0.00 |
| 0312 | 0% | 104 | $0.00 | |
| 87338 | 0% | 22 | $0.00 | |
| 0278 | 0% | 14 | $0.00 | |
| 87329 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOSTA, MARK (SVP AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Tustin, CA | $860K |
| Kaiser Foundation Hospitals | Anaheim, CA | $668K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.